Humana Inc. (HUM) shares surged 5.11% in pre-market trading on Wednesday following the release of its impressive second-quarter 2025 financial results and upgraded full-year guidance. The health insurance giant demonstrated its ability to navigate the challenging healthcare landscape while delivering strong performance.
The company reported adjusted earnings per share (EPS) of $6.27 for Q2, surpassing analysts' expectations of $5.92. Revenue for the quarter reached $32.39 billion, also beating the estimated $31.89 billion. Notably, Humana's medical cost ratio came in at 89.7%, aligning with expectations and indicating effective management of healthcare costs.
Boosting investor confidence, Humana raised its full-year 2025 adjusted EPS guidance to approximately $17.00, up from the previous estimate of $16.25 and exceeding the consensus forecast of $16.38. The company also increased its revenue guidance to at least $128 billion, up from the previous range of $126-128 billion. This optimistic outlook, coupled with the strong Q2 performance, reflects Humana's confidence in its Medicare Advantage business and value-based care strategies, driving the pre-market stock surge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.